24 results
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
30 Nov 21
Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
4:04pm
that develop and commercialize innovative biopharmaceuticals to address important unmet medical needs. Since 2005, 61 Frazier Life Sciences portfolio … innovative products and technologies and bringing them to serve the growing unmet medical needs in the Greater China region by building new ventures
DFAN14A
KDNY
Chinook Therapeutics Inc
12 Jun 23
Additional proxy materials by non-management
9:41am
https://twitter.com/novartisnews
MEDIA & INVESTOR RELEASE
Novartis bolsters innovative medicines strategy and renal pipeline with agreement … to customary closing conditions, is fully in line with Novartis strategy to focus on innovative medicines and will significantly expand its renal
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
21 Nov 16
Other Events
12:00am
three diverse immunotherapy platforms, we believe we are uniquely positioned to bring innovative therapies to patients with late-stage cancers
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
18 Apr 19
Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
4:10pm
on developing and commercializing innovative therapies for women's health and prostate cancer, Mr. Karbe served as executive vice president and chief financial
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
28 Jul 23
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
8:15am
-APRIL monoclonal antibody.
“Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option
DEFM14A
ysxg 28uea9zrnulzg5
10 Jul 23
Proxy related to merger
4:01pm
PREM14A
m6xlgpi7
27 Jun 23
Preliminary proxy related to merger
4:02pm
PRE 14A
aurm75bnjw qxjfj1b
17 Apr 23
Preliminary proxy
4:51pm
DRS
ci51j pwa3qu
19 Dec 14
Draft registration statement
12:00am
DRS/A
5rrf4 9wvjq6cy
28 Jan 15
Draft registration statement (amended)
12:00am
10-K
9uilke
8 Mar 16
Annual report
12:00am